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Serum levels of interleukin-23 and 35 in patients with and 
without type 2 diabetes mellitus and chronic periodontitis 
 
 
Abstract 
Background: Type 2 diabetes mellitus (DM) and chronic periodontitis (CP) show common 
pathophysiological features. We investigated the serum levels of IL-23 and IL-35 in people 
with type 2 DM and CP. 
Methods: In a cross-sectional study, 72 patients were divided into four equal groups: 
group A, participants without type 2 DM and CP; group B, patients with type 2 DM 
without CP; group C, patients with CP and without type 2 DM; and group D, patients with 
type 2 DM and CP. Demographic data were obtained and periodontal conditions including 
clinical attachment loss, bleeding on probing, plaque index, gingival index, and probing 
depth was evaluated on all existing teeth. Fasting blood sugar (FBS) levels, hemoglobin 
(Hb) A1c, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were 
assessed. In addition, serum levels of IL-23 and 35 were measured using enzyme-linked 
immunosorbent assay. 
Results: The serum levels of IL-23 and 35 showed no significant differences between all 
groups (P>0.05). A significant positive correlation between the serum concentration of IL-
23 and clinical attachment loss in the control group (r: 0.548, P=0.019) was detected. A 
significant negative correlation between IL-35 and the plaque index in group B (r: -0.578, 
P=0.012), plus significant negative correlations between IL-23 with ESR (r: -0.487, 
P=0.040) and CRP (r: -0.498, P=0.035) in groups C and D were also detected. 
Conclusion: Despite significant associations of serum concentration of IL-23 and 35 with 
certain periodontal and inflammatory indices, neither type 2 DM nor CP differentially 
affects serum levels of these two cytokines. 
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Periodontitis is an inflammatory condition of the teeth-protecting tissues that is 
induced mostly by gram-negative and anaerobic species microorganisms (1, 2).
 
Periodontitis results in progressive degeneration of periodontal ligaments, alveolar bone, 
gingiva, and eventual loss of teeth (3). Gingival plaques contain living bacteria and their 
biofilm bacteria products such as lipopolysaccharides (LPS) that induce inflammation. The 
inflamed tissues then release inflammatory cytokines into the bloodstream as signaling 
proteins (4). On the other hand, diabetes mellitus (DM) is known as a significant risk 
factor for periodontitis (5, 6). Persistent hyperglycemia, which is seen in prediabetes and 
diabetic patients, induces damages in the periodontal tissues due to the changes in the 
activity of polymorphonuclear cells and leukocytes plus alteration of glycosaminoglycans 
and cytokines production (7).  
 Caspian J Intern Med 2019; 10(3):xx295-302 
296                                                                             Maboudi A, et al. 
Thus, patients with type 2 DM have a high prevalence of 
gingivitis, periodontitis, oral candidiasis, and xerostomia 
(dry mouth). The severity of these diseases depends on the 
duration of the patient's diabetes (8). 
Interleukin (IL)-23, which is a signaling protein in 
inflammatory conditions of periodontitis, also plays a role in 
mild degrees of type 2 DM-related inflammation (9). In 
chronic infections, antigens stimulate dendritic cells, 
macrophages, and IL-23 production that motivates the 
production of IL-17. Also, IL-23 increases the production of 
IL-6, IL-1 and tumor necrosing factor (TNF)-α in the 
autocrine/paracrine pathway (10). Moreover, IL-35 is an 
anti-inflammatory cytokine in the IL-12 family that plays a 
suppressive role in the immune system (11). Since IL-23 is 
involved in the pathogenesis of type 2 DM and chronic 
periodontitis (CP), and there are controversies in some 
studies (12, 13) and lack of any data about the role of IL-35, 
we aimed to investigate the serum levels of IL-23 and IL-35 
in people with type 2 DM and CP and compare them with 
the control group. 
 
 
Methods 
Patients: The current cross-sectional study was done in 2016 
with the coordination of three private and public dental 
centers of Sari, North of Iran. Based on the prevalence of CP 
and DM and the following formula, α=0.05 was considered 
significant, and the beta level was set at β=0.10. 
Additionally, four study groups and a sample size of 18 
patients per group were calculated for this preliminary study. 
Based on convenience sampling method, referred patients 
were followed-up to identify those with DM based on the 
criteria of the American Association of Diabetes (14) and 
patients with CP based on the existence of inflammation in 
the periodontium (15).  
Briefly, type 2 DM was confirmed if one of the following 
conditions was reported: (a) fasting blood sugar (FBS) ≥ 126 
mg/dL; (b) random blood sugar ≥ 200 mg/dL with signs of 
hyperglycemia; and (c) HbA1c ≥ 6.5%. Periodontitis was 
also diagnosed in patients with at least one site with ≥ 3 mm 
probing depth and ≥ 2 mm loss of clinical attachments. 
Exclusion criteria were: patients younger than 18 year, 
progressed renal failure with serum creatinine level > 2 
mg/dL, class III and IV heart failure, hepatic failure, use of 
certain drugs that induce insulin resistance and 
hyperglycemia such as prednisolone, cyclosporine and etc., 
consumption of antibiotics during the past three months, 
being treated for periodontitis, smoking during pregnancy, 
hemorrhagic diseases, and those who had less than 14 teeth 
(Fig. 1). Four groups, each with 18 patients were defined as 
follows: 
Group A: participants with neither type 2 DM nor CP 
Group B: patients with type 2 DM based on laboratory test 
and without CP based on clinical examination 
Group C: patients with CP and without type 2 DM 
Group D: patients with type 2 DM and CP 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Flow chart of patients’ enrollment. DM, diabetes mellitus; CP, chronic periodontitis. 
 
The Ethics Committee of Mazandaran University of 
Medical Sciences approved the protocol of the study (No.  
 
13959); hence, all investigations have been carried out in 
accordance with the principles of the Declaration of Helsinki 
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as revised in 2008. Moreover, the aims of the study were 
described completely for all enrolled participants and written 
consent informs were obtained. 
Evaluations: A face-to-face questionnaire about 
demographic data, familial history of type 2 DM, and 
education level was filled out. Then, the periodontal examination 
was performed using a mirror and a periodontal probe 
(Williams probe, Medisporex, Pakistan). Clinical attachment 
loss (CAL) (16), bleeding on probing (BOP) (17), plaque 
(Loe) index (PI) (18), gingival index (GI) (19) and probing 
depth (PD) (20) for all teeth were recorded by an expert 
dentist (the first author). Her correlation coefficient of 
measurements was 0.84 in the previous pilot study using five 
CP patients and two measurements with a one-week interval. 
Serum measurements: About 4 ml of fasting blood samples 
obtained from the cubital vein into sterile vacutainers 
without anticoagulant and serum were harvested after 
centrifugation (3000 RPM, 10 min). Serums were used for 
measurements of FBS (mg/dL) using an enzymatic 
colorimetric method (GOD/PAP) by an autoanalyzer prestige 
24i (Tokyo Boeki Medical System, Japan), C-reactive 
protein (CRP, mg/l) by the nephelometric method, IL-23 and 
IL-35 concentrations (pg/ml) using the sandwich ELISA 
(Ebioscience, San Diego, CA, USA). Another 2 ml of the 
previously drawn blood was placed into the EDTA tube used 
for measuring HbA1c (%) using the Nycocard Reader II and 
erythrocyte sedimentation rate (ESR) (mm/h) by the manual 
method (21, 22). 
Our analysis variables had a biological nature and a 
normal distribution in the population. In addition, we 
checked the data by the Kolmogorov-Simonov test, and find, 
with the exception of one or two data that was far from 
average, all other data had a normal distribution. Therefore, 
we handled and analyzed them using parametric analyses. 
All statistical analyses were performed using the software 
SPSS Version 23. Comparison of age, serum, blood 
biomarkers, and periodontal indices between the four groups 
was performed using the one-way analysis of variance 
(ANOVA) and Tukey's Post Hoc test. Associations between 
jobs, education, systemic diseases, familial history of type 2 
DM, gender, severity, and distribution of periodontal 
diseases with type 2 DM and CP were checked using the chi-
square test. Associations between serum concentrations of all 
quantitative variables were checked using the Pearson’s 
correlation test. A p<0.05 was considered as the significant 
difference.  
Results 
Subjects in the healthy control group had a significantly 
lower age (P<0.001) and a higher number of teeth (P<0.05) 
in comparison with the other three groups. Since the 
enrollment criteria for the study patients did not include their 
sex, our four groups were not sex-matched (P<0.001); hence, 
we had a higher frequency of females in the all groups 
except the CP group. Most of the participants were 
unemployed or homemakers (44.4%) while the others had a 
diploma or associate degree (38.9%) and were without 
systemic diseases (73.6%) or familial history of DM 
(52.8%).  
Generalized moderate periodontitis was the most 
frequent form of periodontal diseases in both CP and 
DM+CP groups (66.7% and 44.4%, respectively) followed 
by severe diffused periodontitis (16.7% and 38.9% 
respectively, table 1). FBS and HbA1c were significantly 
higher in the DM and DM+CP groups in comparison with 
the other two groups, but no significant differences were 
detected between these two groups with regard to FBS or 
HbA1c levels.As shown, all periodontal indices in the CP 
and DM+CP groups were significantly higher than related 
indices in the control and DM groups (P<0.05). Despite the 
significantly lower GI index in the DM+CP group compared 
with the CP group (P=0.03), no significant differences were 
detected between the control and DM groups, or the CP and 
DM+CP groups (p>0.05). 
Accordingly, fig. 2 shows that the DM+CP showed 
higher inflammation in comparison to the control group, 
which was based only on higher ESR. However, CRP, IL-23, 
and IL-35 levels showed no significant differences between 
the four groups. As a secondary finding, comparisons of 
periodontal indices of the mandible and maxilla were 
performed separately.  
Our findings were similar to the total indices that have 
been presented above, except for the lack of significant 
difference in the PD of the maxillary teeth between the 
DM+CP and the other three groups and in the GI of the 
mandible and maxilla between the DM+CP and CP group 
(p<0.05, data not shown).  
Significant negative correlations were seen between IL-
35 with PI in DM group; IL-23 with HbA1c and ESR in CP 
group and between IL-23 with CRP in DM+CP group. 
Moreover, significant positive correlations were detected 
between IL-23 with age and CAL in the control group and 
between IL-23 and PI in the CP group. 
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Table 1. Demographic characteristics of patients in four groups. 
 Groups  
Variables Health (n=18) DM (n=18) CP (n=18) DM+CP (n=18) Total 
Age (years) 27.44±10.07
a 
46.06±10.53
b 
44.78±13.18
b 
52.72±9.96
b 
 
Number of tooth 29.00±2.59
a 
24.50±5.37
b 
24.94±4.14
b 
24.33±4.70
b 
 
Gender      
Male 5 (27.8) 3 (16.7) 14 (77.8) 3 (16.7) 25 (34.7) 
Female 13 (72.2) 15 (83.3) 4 (22.2) 15 (83.3) 47 (65.3) 
HbA1c 5.51±0.36
a 
8.53±1.00
b 
5.79±0.45
a 
8.12±1.09
b 
 
FBS 86.56±5.23
a 
184.00±68.91
b 
89.44±8.91
a 
154.39±43.55
b 
 
Periodontal indices      
     Upper tooth      
CAL 0.72±2.27
a 
3.72±6.26
a 
47.61±31.35
b 
46.83±29.97
b 
 
BOP 8.17±6.53
a 
15.17±11.62
a 
33.33±17.16
b 
31.55±13.98
b 
 
PI 25.06±23.63
a 
47.17±22.26
a 
81.67±37.11
b 
72.94±19.42
b 
 
GI 32.11±26.43
a 
43.67±29.10
a 
102.44±44.32
b 
74.50±27.44
b 
 
PD 89.11±21.71
a 
89.94±23.87
a 
118.83±33.06
b 
111.17±26.59
ab 
 
     Lower tooth      
CAL 3.11±5.78
a 
4.39±5.65
a 
64.39±35.30
b 
92.61±55.30
b 
 
BOP 5.61±4.50
a 
12.11±9.85
a 
38.89±15.49
b 
32.44±15.93
b 
 
PI 28.78±22.67
a 
41.72±17.16
a 
95.67±33.39
b 
88.94±25.46
b 
 
GI 28.44±25.58
a 
39.50±26.95
a 
110.00±28.20
b 
83.78±31.67
b 
 
PD 85.22±13.17
a 
77.00±28.53
a 
124.50±25.15
b 
113.50±33.55
b 
 
Jobs      
UE or housekeeper 0 (0) 11 (61.1) 7 (38.9) 14 (77.8) 32 (44.4) 
Self-employment 3 (16.7) 4 (22.2) 8 (44.4) 3 (16.7) 18 (25.0) 
Employee 14 (77.8) 2 (11.1) 3 (16.7) 1 (5.6) 20 (27.8) 
Retired 1 (5.6) 1 (5.6) 0 (0) 0 (0) 2 (2.8) 
Education      
Before the diploma 0 (0) 8 (44.4) 8 (44.4) 10 (55.6) 26 (36.1) 
Diploma or AD 4 (22.2) 8 (44.4) 8 (44.4) 8 (44.4) 28 (38.9) 
BSc and higher 14 (77.8) 2 (11.1) 2 (11.1) 0 (0) 18 (25.0) 
Systemic diseases      
No 18 (100) 10 (55.6) 16 (88.9) 9 (50.0) 53 (73.6) 
Hypertension 0 (0) 2 (11.1) 0 (0) 6 (33.3) 8 (11.1) 
Thyroid disorders 0 (0) 3 (16.7) 0 (0) 1 (5.6) 4 (5.6) 
CVDs  0 (0) 0 (0) 1 (5.6) 1 (5.6) 2 (2.8) 
Others 0 (0) 3 (16.7) 1 (5.6) 1 (5.6) 5 (6.9) 
Familial history of DM      
Yes 1 (5.6) 16 (88.9) 2 (11.1) 15 (83.3) 34 (47.2) 
No 17 (94.4) 2 (11.1) 16 (88.9) 3 (16.7) 38 (52.8) 
Periodontitis      
No 18 (100) 18 (100) 0 (0) 0 (0) 36 (50.0) 
Localized mild 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Generalized mild 0 (0) 0 (0) 2 (11.1) 3 (16.7) 5 (6.9) 
Localize moderate 0 (0) 0 (0) 1 (5.6) 0 (0) 1 (1.4) 
Generalized moderate 0 (0) 0 (0) 12 (66.7) 8 (44.4) 20 (27.8) 
Localized severe 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Generalized severe 0 (0) 0 (0) 3 (16.7) 7 (38.9) 10 (13.9) 
UE, un-employed; AD, associate degree; CVDs, cardiovascular diseases; CAL, clinical attachment loss; BOP, bleeding on probing; PI, plaque (Loe) index; GI, 
gingival index; PD, probing depth.  Different superscript letters in each row indicate statistical significant difference (P<0.05). 
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Figure 2. Comparison of serum biochemical indices of diabetes and inflammation between the four groups. DM, diabetes 
mellitus; CP, chronic periodontitis. Significant statistical differences between groups were indicated by different 
superscript letters (P<0.05). 
 
Discussion 
In the preset study, patients with DM+CP showed higher 
inflammation (ESR index) in comparison to the control 
group while CRP, IL-23, and IL-35 levels were similar 
between the four groups. 
Periodontal disease is the sixth most common 
complication of DM (23), and these two diseases have 
common pathophysiological mechanisms that have been 
confirmed by animal (24) and human studies (25). Also, 
patients with uncontrolled DM show a higher prevalence of 
periodontal diseases (26). It has been reported that DM-
induced over-expression of IL-17 as a pro-inflammatory 
cytokine (27) in addition to its stimulated expression by IL-
23 (28). These two cytokines along with other inflammatory 
molecules and cells play important roles in the common 
pathological pathway of DM and CP (29). However, we 
found no significant difference in the serum concentration of 
IL-23 between our four groups.  
Similar to our findings, Vieira Ribeiro et al., by 
evaluating different cytokines in healthy patients with DM 
and chronic periodontitis reported that no significant 
difference in the level of IL-23 among healthy and controlled 
diabetic patients (13). Furthermore, Duarte et al. reported 
that CP- not DM- significantly altered the expression of the 
immune system and inflammatory markers related genes 
such as IL-23 (30), which is similar to our report about DM  
 
but opposite regarding CP. Moreover, santos et al. 
detected significant differences in the gingival crevicular 
fluid (GCF) level of IL-4 and IL-17, not IL-23, between 
well-controlled and poorly controlled DM subjects with CP 
before and after periodontal therapy (12). Changes in the IL-
17 without any changes in the IL-23 may be due to the 
regulatory roles of other cytokines involved in the 
stimulation of IL-17which affect the proliferation and 
differentiation of Th17 as the producers of IL-17. On the 
other hand, there may be differences in the source of the 
biomarker used in the different studies, which could 
potentially cause the controversial findings. For instance, the 
inflammatory role of IL-23 was reported by assessing this 
biomarker in the gingival biopsy (31) and GCF (32) of 
patients with CP. However, when we assessed the serum 
level of IL-23, we did not confirm such role.  
Significant negative correlations between IL-23 with 
ESR and CRP in the CP and DM+CP groups were seen, 
respectively, which seems irrational due to the inflammatory 
nature of all mentioned parameters. Significant positive 
correlation between the serum concentration of IL-23 and 
CAL in the control group was also reported previously in 
gingivitis and periodontitis tissues (33). In addition, novel 
significant positive correlation between serum IL-23 
concentration and GI is rational and could be investigated 
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further in future research. There are no reports about the 
comparison of serum levels of IL-35 between patients with 
and without DM and CP. In addition, no studies have 
evaluated IL-35 and IL-23 concurrently in DM. Only one 
study evaluated the expression of IL-23 and IL-35 in GCF 
and serum of CP and compared their levels with healthy 
volunteers. They found that the GCF and serum levels of 
both cytokines were elevated in CP patients (34). Moreover, 
an increase in the serum level of IL-35 in patients with both 
types of DM (35) and periodontal diseases (36) were 
reported separately. Due to the immunosuppressive role of 
IL-35 and its selective activities to proliferate regulatory T 
cells and suppress Th17 cells (37), the negative associations 
between IL-23 and IL-35 is conceivable. However, such a 
relationship was not detected in our study, which may be 
related to the evaluation of both biomarkers in the serum - 
not GCF or gingival biopsy. Contrary to those reported by 
Koseoglu et al. in the GCF of patients with chronic 
periodontitis (38), the significant negative correlation 
between IL-35 and PI in DM group was found in this study, 
which is also rational based on the anti-inflammatory 
properties of this immunosuppressive cytokine. This result is 
about similar to the recent finding of Kaustubh et al. about 
significantly higher GCF IL-35 levels in a healthy population 
compared with patients with gingivitis (39).  
Other non-significant correlations between any 
periodontal indices and serum concentrations of IL-35 could 
reinforce this hypothesis that periodontitis and gingivitis 
induce no changes in the expression of IL-35. However, a 
recent study by Kaustubh et al. has reported the suppressing 
role of IL-35 in gingival inflammation and maintaining 
periodontal health (40). For more validation and 
confirmation, it is recommended to evaluate the 
concentration of IL-35 in GCF and saliva in healthy 
participants and patients with periodontitis and gingivitis. 
Despite our findings, the low number of patients in each 
group was the one important limitation of our study. The 
limitation was due to our inclusion/exclusion criteria that 
limited the number of patients with diabetes and 
periodontitis with a minimum number of 14 teeth.  
In conclusion, no significant differences in the serum 
levels of IL-23 and IL-35 were detected between patients 
with and without DM and CP in this preliminary case-
control study. It seems that the role of these two ILs should 
be further evaluated and confirmed in future research, 
especially cohort studies. 
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